1、Positron Emission Tomography,Radioisotopes in PET,各種常用正子放射核種的特性： IsotopeT1/2 (min)Emax (MeV)FWHM (mm) F-18109.70.6350.22 C-1120.40.960.28 N-139.961.190.60 O-152.071.721.1 Ga-6868.31.901.35 Rb-821.253.352.6,Positron emitted Radiopharmaceuticals,PET scanner,FDG PET in Normal,PET in Oncology,顯影藥物：FDG,
2、C-11 methionine, N-13 glutamate, F-18 FU, F-18 misonidazole, etc.良性、惡性腫瘤鑑別癌症病灶偵測定位偵測癌症淋巴腺及轉移病灶精確的癌症分期癌症復發、壞死鑑別藥物、受體分析癌症篩檢,FDG accumulation in cancer cells,Action of glucose transporter proteinsHighly active hexokinase bound to tumor mitochondria helps to trap FDG into cellRelative hypoxia in tumor m
3、asses which activate the anaerobic glycolytic pathway,FDG uptake in cancer cells,The increased glucose uptake is due to the need for nucleic acid synthesis and, therefore, is directly related to the tumors tendency to grow. Minn et al.FDG uptake is strongly related to the number of viable tumor cell
4、s, although not directly regulated by the need for DNA synthesis. Higashi & Haberkorn,Cancer 1988:1776, JNM 1991:1548, JNM 1993:414,Health Care Finance Administration,www.hefa.gov 12/2000,臨床症狀肺癌（非微小可疑點）黑色素瘤結腸癌淋巴瘤食道癌頭頸癌腦疾發作（如癲癇）心肌存活乳癌阿茲海默症,給付類別診斷、分期、再分期診斷、分期、再分期（局部結點除外）診斷、分期、再分期診斷、分期、再分期診斷、分期、再分期診斷、分
5、期、再分期手術前評估SPECT 未有結論時之追蹤MCAC 研究中MCAC 研究中,PET/CT in Esophageal cancer,PET in Neurology,顯影藥物：FDG, C-11 NMSP, F-18 L-dopa, C-11 benzodiazepine, C-11 carfentanil, etc.老年癡呆症早期診斷癲癇病灶偵測定位腦瘤良性、惡性、壞死腦血管疾病早期診斷癌症復發、壞死鑑別椎體外神經系統疾病精神疾病,FDG PET in Alzheimers disease,PET in Cardiology,顯影藥物：FDG, C-11 palmitate, C-11
6、 acetate, N-13 NH3, F-18 misonidazole, etc.存活心肌 PTCA, CABG 術前評估、術後追蹤心肌梗塞範圍、預後冠心症診斷、嚴重度 、側支循環Dilated or Ischemic 心肌病變鑑別診斷,PET/CT or PET/MR : Clinical Benefits,Improved oncological diagnosisimproved localization of diseaseassistance with biopsy guidancemonitoring chemo- & radiation therapyradiation therapy planningfaster PET scanning time,JNM 2000 (8):,
